| 查看: 2624 | 回复: 9 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
williamxiang木虫 (著名写手)
|
[交流]
FDA批准第一个SGLT-2抑制剂类降血糖药－canagliflozin 已有4人参与
|
||
|
美国FDA于当地时间2013年3月29日发布消息称，该机构于日前批准了第一个钠－葡萄糖同向转运体－2抑制剂类Ⅱ型糖尿病治疗用药－来自强生制药的canagliflozin，商品名Invokana。 但是，FDA在做出批准的同时还要求强生公司于该药上市后进行5项研究，包括心血管研究、药物监测研究、骨骼安全性研究与两项儿科研究。 Thomson Reuters的分析人士称，Invokana有望于2016年实现4.68亿美元的销售额。 田边制药株式会社于2004年7月30日所申请的第200480022007.8号专利是为canagliflozin在中国的化合物专利，该专利申请及其分案申请均尚处于实质审查阶段。 [ Last edited by williamxiang on 2013-4-2 at 11:11 ] |
回复此楼» 猜你喜欢
二糖的糖脂，合成后sephadex LH-20分离不出来，求助
已经有1人回复
-
南方医科大学珠江医院肖计生课题组招收博士生 （2026年入学）
已经有2人回复
-
药理学论文润色/翻译怎么收费?
已经有64人回复
-
349药学专硕105500求调剂
已经有0人回复
-
求调剂
已经有1人回复
-
298求调剂一志愿中海洋
已经有3人回复
-
药学调剂申请自荐信，一志愿中南大学
已经有1人回复
-
药学349专硕求调剂
已经有1人回复
-
《左乙拉西坦注射液制备工艺研究、质量控制和稳定性研究》下载
已经有1人回复
-
中国医药行业发展现状：标准品推动药品检测水平提升
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- FDA批准强生Canagliflozin用于2型糖尿病
已经有8人回复
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
最早的专利是2005申请 Patents Company Title Publication details Type Inventors Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner) Formulation for co-therapy treatment of diabetes WO-2012006298.12-JAN-2012 ( 06-JUL-2010 ) . . Component of Combination Delaet, Urbain, Alfons Clementina; Faure, Anne; Heyns, Philip, Erna Hortentia Gilbert; Jans, Eugeen, Maria Jozef; Railkar, Aniruddha Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner) Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT WO-2011143296.17-NOV-2011 ( 11-MAY-2010 ) . . Formulation Wang, Wenhua; Outwin, Todd; Joseph, Thomas C. Mitsubishi Tanabe Pharma Corp [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Canagliflozin containing tablets WO-2011142478.17-NOV-2011 ( 11-MAY-2010 ) . . Formulation Sugimoto Masaaki; Kinoshita Hajime; Tokuda Takayuki Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner) Process for the preparation of compounds useful as inhibitors of SGLT2 WO-2011047113.21-APR-2011 ( 14-OCT-2009 ) . . Process Farina, Vittorio; Lemaire, Sebastien, Francois Emmanuel; Houpis, Ioannis, N. Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner) Crystallisation process for 1-(ß-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene WO-2011003976.13-JAN-2011 ( 10-JUL-2009 ) . . Process Rammeloo, Thomas Joachim Landewald; De Keyser, Ruben; Schildermans, Gustaaf Jozef Petrus Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner); Mitsubishi Tanabe Pharma Corp [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Process for the preparation of compounds useful as inhibitors of SGLT WO-2010043682.22-APR-2010 ( 17-OCT-2008 ) . . Process Filliers, Walter Ferdinand Maria; Broeckx, Rudy Laurent Maria; Nieste, Patrick Hubert J.; Hatsuda, Masanori; Yoshinaga, Masahiko; Yada, Mitsuhiro Mitsubishi Tanabe Pharma Corp [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Combination therapy comprising SGLT inhibitors and DPP-4 inhibitors WO-2009091082.23-JUL-2009 ( 17-JAN-2008 ) . . Component of Combination Ueta, Kiichiro; Arakawa, Kenji; Matsushita, Yasuaki Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner); Mitsubishi Tanabe Pharma Corp [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Process for the preparation of compounds useful as inhibitors of SGLT WO-2009035969.19-MAR-2009 ( 10-SEP-2007 ) . . Process; Product (derivative) Abdel-Magid, Ahmed F.; Chisholm, Maureen; Mehrman, Steven; Scott, Lorraine; Wells, Kenneth M.; Zhang-Plasket, Fan; Nomura, Sumihiro; Hongu, Mitsuya; Koga, Yuichi Mitsubishi Tanabe Pharma Corp [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate WO-2008069327.12-JUN-2008 ( 04-DEC-2006 ) . . Product (derivative) Nomura, Sumihiro; Kawanishi, Eiji Janssen Pharmaceutica NV [Johnson & Johnson] (Patent Assignee/Owner); Tanabe Seiyaku Co Ltd [Mitsubishi Chemical Holdings Corp] (Patent Assignee/Owner) Substituted indazole-O-glucosides WO-2005011592.10-FEB-2005 ( 01-AUG-2003 ) . . Product Patel, Mona; Rybczynski, Philip; Urbanski, Maud; Zhang, Xiaoyan |
7楼2013-04-02 15:15:45
3楼2013-04-01 12:55:30
williamxiang
木虫 (著名写手)
- DRDEPI: 2
- 应助: 122 (高中生)
- 金币: 3506.2
- 散金: 56
- 红花: 30
- 帖子: 1375
- 在线: 720.1小时
- 虫号: 1070371
- 注册: 2010-08-06
- 性别: GG
- 专业: 药物资源
4楼2013-04-01 13:14:17
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Thomson Reuters的报告没有提供数据， 见下： Sales Comment Consensus forecast data for Johnson & Johnson (J&J) and Mitsubishi Tanabe Pharma are presented. In July 2000, Tanabe (now Mitsubishi Tanabe) licensed the worldwide development and marketing rights, excluding Japan and parts of Asia, to J&J [377554]. In March 2012, Mitsubishi Tanabe and Daiichi Sankyo entered into a strategic alliance to copromote canagliflozin in Japan [1269148]. 不知楼主从哪里得到的市场信息？ |
5楼2013-04-02 13:39:46
